



## **Lypro Biosciences announces commercial launch of Ambigent™, an antifungal reagent for high value cell cultures**

May 1, 2015

Berkeley, CA – Lypro Biosciences, Inc. (Lypro Bio) is now offering to the research market Ambigent™, an antifungal for high value cell cultures, such as stem cells. Ambigent™ provides the trusted anti-mycotic power of amphotericin-B (AMB) wrapped in the novel NanoDisk bioactive agent delivery platform. NanoDisk provide a super-solubilizing vehicle for AMB, improving bioavailability to enhance anti-mycotic action. Experimental results show little or no toxicity toward treated cells and no deleterious effects on cell viability.

Ambigent™ is added to cell culture media to prevent yeast and fungal contamination. The cultivation of eukaryotic cells continues to be a critical component of biological and pharmaceutical research but, even though technical precautions are often taken, contamination of tissue culture media remains a real and costly concern. Researchers working with high value cell cultures and those that may not have access to fully sterile operations will be interested in this novel formulation of AMB for cell culture protection.

NanoDisk are non-toxic, biodegradable nanoparticles which increase the solubility and bioavailability of the bioactive agent. Detergent-free by design, Ambigent™ allows the researcher to gain the protective effects of AMB and avoid detergents such as deoxycholate typically used in other AMB formulations. Lypro Bio has exclusive rights to the patent technology.

Ambigent™ is for research use only. Please contact [info@lyprobio.com](mailto:info@lyprobio.com) for inquiries about Ambigent™.

### About Lypro Biosciences

Lypro Biosciences, Inc. is privately-held, nanotechnology company, located in the San Francisco Bay Area. Lypro Bio's proprietary nanotechnology drug delivery platform, NanoDisk, has applications across numerous disease indications. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancers such as mantle cell lymphoma.

### Contact:

Michelle S. Call  
President and CEO  
Lypro Biosciences, Inc.  
[info@lyprobio.com](mailto:info@lyprobio.com)  
[www.lyprobio.com](http://www.lyprobio.com)

---